Stephen Appezzato

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

FDA commissioner Marty Makary is planning to resign today, according to sources close to the White House.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

The facility opening corresponds with a new $4.5 billion capital commitment across two of Lilly's three sites in Lebanon, Indiana.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

Joel Wayment discusses how the cold chain can be more sustainable.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

Jennifer Lospinoso explains how cell and gene therapies are reshaping specialty pharmacy commercialization.

In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking prescription spending outlook for 2026 and more.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains.

Nico Vandaele shares how advanced modeling and simulations can be used to get ahead of future supply chain disruptions.

Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain transformation.

Shawn McGee discusses today's key risks in the pharma supply chain, and how to prevent disruptions.

In this week’s Pharma Pulse, GEODIS’ cold chain expansion in the Midwest, a potential multi-billion dollar shift in cell therapy, and the White House’s new push for psychedelic mental health treatments.